This is a working overview of human growth hormone, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-28. Anything still debated is marked as such rather than presented as settled.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
==== Agitation of hydrophilic primer or adhesive during application ==== Besides having adequate dentinal moisture, agitation of the primers during application of two-step etch-and-rinse adhesives may be critical for optimal penetration into the demineralized collagen fibres. It also may aid the evaporation of residual water in the adhesive and hybrid layers, thus preventing nano leakage. In a clinical trial comparing the performance of Prime & Bond NT using no rubbing action, slight rubbing action and vigorous rubbing action in the restoration of NCCLs, 92.5% of restorations in vigorous rubbing action group were found to retain after 24 months of clinical service. For the other two groups, the retention rates of the restoration were slightly lower, at 82.5%.
Corneal abrasion – a medical condition involving the loss of the surface epithelial layer of the eye's cornea as a result of trauma to the surface of the eye. Corneal dystrophy – a condition in which one or more parts of the cornea lose their normal clarity due to a buildup of cloudy material. Corneal ulcer – an inflammatory or infective condition of the cornea involving disruption of its epithelial layer with involvement of the corneal stroma. Corneal neovascularization – excessive ingrowth of blood vessels from the limbal vascular plexus into the cornea, caused by deprivation of oxygen from the air. Fuchs' dystrophy – cloudy morning vision. Keratitis – inflammation of the cornea. Keratoconus – a degenerative disease, the cornea thins and changes shape to be more like a cone. Corneal foreign body – a foreign object present in the cornea, one of the most common preventable occupational hazards.
Scientists found that the simple up-regulation of HIF-1a via PHD inhibitors regenerates lost or damaged tissue in mammals that have a repair response; and the continued down-regulation of Hif-1a results in healing with a scarring response in mammals with a previous regenerative response to the loss of tissue. The act of regulating HIF-1a can either turn off, or turn on the key process of mammalian regeneration.
Sources: en.wikipedia.org
This was confirmed by another meta-analysis involving 945 286 patients in 8 retrospective cohort studies, most in the US. In 2012, the U.S. Justice Department announced GlaxoSmithKline had agreed to plead guilty and pay a $3 billion fine, in part for withholding the results of two studies of the cardiovascular safety of Avandia between 2001 and 2007.
. This is consistent with a normal kinetic isotope effect in which the product is slightly depleted in a heavy isotope relative to the reactant. If the isotope effect is small, as is typical for C and N,
where ∆(APB) is the area of triangle APB. Denote the segments that the diagonal intersection P divides diagonal AC into as AP = p1 and PC = p2, and similarly P divides diagonal BD into segments BP = q1 and PD = q2. Then the quadrilateral is tangential if and only if any one of the following equalities are true:
Rather than finding homologous proteins from different species, a new Tag/Catcher pair was developed from SpyTag/SpyCatcher with minimal mutations. SpyTag I3W (AW) reacts with SpyCatcher F77V, F94A (BVA) but minimally with SpyCatcher, whereas SpyCatcher F77V, F94A can react with both SpyTag I3W and SpyTag. However, the cross-reactivity of SpyCatcher F77V, F94A with both SpyTag versions may limit its utility as a new Tag/Catcher pair. A different chemistry can be exploited for protein ligation: the discovery of an intramolecular ester bond formation in Clostridium perfringens cell-surface adhesin protein Cpe0147 led to the development of another Tag/Catcher pair with Cpe0147565–587 as the Tag and Cpe0147439–563 as the Catcher. The ester bond formed between Thr-Gln is irreversible, however by mutating the Thr to Ser, the Ser-Gln ester bond is reversible with a change of pH.
Sources: en.wikipedia.org
=== Secondary and tertiary structures === Chymopapain's structure was solved by X-ray diffraction techniques. Analysis of this structure showed chymopapain to have 7 alpha helix regions, 10 beta sheet regions and 2 loop turns. These 2 turns are the main difference between chymopapain's structure and other papaya proteinase proteins such as papain or caricain, which have similar conformations. Besides, chymopapain presents 3 disulfide bonds as post-traducional modifications stablished between residues 156–197, 190–229 and 287–338.
== Commercial situation == As of 2017, Cytiva holds patents around three-column periodic counter-current chromatography: this technology is used in their Äkta PCC instrument. Likewise, ChromaCon holds patents for an optimized two-column version (CaptureSMB). CaptureSMB is used in ChromaCon's Contichrom CUBE and under license in YMC's Ecoprime Twin systems. Additional manufacturers of systems capable of periodic counter-current chromatography include Novasep and Pall.
Sections of human skin can be found in the collections of some museums. Some examples of this include books bound with human skin (anthropodermic bibliopegy) and preserved tattoos. The largest collection of the latter can be found in the Wellcome Collection at the Science Museum, London. American artist Andrew Krasnow has caused controversy in recent decades by creating pieces of contemporary art made of human skin. His works, which often make political statements, are composed of pieces of flesh from individuals who have donated their bodies to science. The skin itself has been preserved by tanning.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.